Asthma and lower airway diseaseSafety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients
Section snippets
Patients
Eligible patients were aged 18 to 65 years, had moderate-to-severe asthma, and were receiving stable inhaled corticosteroids (ICSs; ≥200 and ≤1000 μg/d fluticasone or equivalent) for 30 or more days, with consecutive use for at least the prior 3 months before screening. Patients were recruited from each clinical site’s pool of patients or from referral and selected based on key inclusion criteria, which included ongoing asthma symptoms with Asthma Control Questionnaire (ACQ) scores of 1.5 or
Disposition
A total of 397 patients were randomized (placebo, n = 79; 5 mg of AMG 853 BID, n = 80; 25 mg of AMG 853 BID, n = 79; 100 mg of AMG 853 BID, n = 79; and 200 mg of AMG 853 QD, n = 80), and 396 received investigational product. One patient enrolled into the 5-mg AMG 853 BID group but did not meet eligibility requirements and therefore did not receive investigational product. Of all patients randomized, 351 (88.4%) completed the study. Forty-six patients prematurely discontinued the study, with 7
Discussion
This study provides the first clinical data to date examining the effects of a CRTH2 and DP dual antagonist as add-on treatment to ICS therapy in asthma. The findings from this study suggest that AMG 853, when evaluated as add-on treatment to ICSs in patients with moderate-to-severe persistent asthma whose symptoms are not fully controlled with ICSs, demonstrated no improvement in control of asthma or modifying biomarkers. The adverse events observed after AMG 853 treatment would not preclude
References (24)
- et al.
Prostaglandin D(2) Receptor CRTH2 Antagonists for the Treatment of Inflammatory Diseases
Prog Med Chem
(2011) - et al.
Single-dose, first-in-human study of AMG 853: Pharmacokinetics, pharmacodynamics, and safety in healthy adults
J Allergy Clin Immunol
(2010) - et al.
Albumin-catalyzed metabolism of prostaglandin D2. Identification of products formed in vitro
J Biol Chem
(1983) - et al.
Metabolic fate of endogenously synthesized prostaglandin D2 in a human female with mastocytosis
Prostaglandins
(1985) - et al.
Identifying “well-controlled” and “not well-controlled” asthma using the Asthma Control Questionnaire
Respir Med
(2006) - et al.
Validation of a standardized version of the Asthma Quality of Life Questionnaire
Chest
(1999) - et al.
New insights into the generation of Th2 immunity and potential therapeutic targets for the treatment of asthma
Curr Opin Allergy Clin Immunol
(2011) - et al.
Prostaglandin D2 as a mediator of allergic asthma
Science
(2000) - et al.
Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2
J Exp Med
(2001) - et al.
Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE
J Immunol
(1982)
Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751
J Pharmacol Exp Ther
A prostaglandin D2 receptor antagonist modifies experimental asthma in sheep
Clin Exp Allergy
Cited by (0)
Supported by Amgen.
Disclosure of potential conflict of interest: W. W. Busse has served on the advisory board for Merck; has consultant arrangements with Amgen, AstraZeneca, Novartis, GlaxoSmithKline, MedImmune, and Genentech; has received research support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases and the NIH/National Heart, Lung, and Blood Institute. S. E. Wenzel has received research support from Amgen. E. M. Kerwin has received research support from Amgen; has served on advisory boards or speakers' panels for Astra Zeneca (MAP Pharma), Dey Laboratories, Ironwood Pharmaceuticals, Pfizer, Sanofi Aventis, Sunovion (Sepracor), and Targacept; has received travel reimbursement from Merck (Schering-Plough), Forest Labs, and Novartis; has conducted clinical research trials for Abbott, Actelion, Adams, Alcon, ALK-Abelló, Allergy Therapeutics, Almirall, Amgen, Amphastar, Astellas, Astra Zeneca (MAP Pharma), Asubio, Biota, Boehringer Ingelheim, Cephalon (Centocor, Ception), Chiesi, Critical Therapeutics, Daiichi Sankyo, Dey Labs, Elevation Pharma, Elixir, Exelixis, Forest, Genentech, GlaxoSmithKline, Incyte, Inflazyme, Johnson & Johnson, Lilly, Meda, Medicinova, MedImmune, Med Pointe, Merck (Schering-Plough), Mpex, Novartis, Novo Nordisk, Otsuka, Pearl, Pfizer (Wyeth), Phenomix, Replidyne, Roche, Sanofi-Aventis, Skye Pharma, Stallergenes, Sunovion (Altana, Sepracor), TAP, Takeda, Targacept, Teva (Ivax), UCB Pharma, and Wellstat. M. C. Liu has received research support from GlaxoSmithKline, MedImmune, Sanofi-Aventis, and Amgen and has served on the Data Safety Monitoring Board for Cephalon. N. Zhang, A. L. Budelsky, J. Lin, and S.-L. Lin are employed by Amgen. Y. Chon is employed by and holds stock in Amgen. The rest of the authors declare that they have no relevant conflicts of interest.